Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection

Abstract

Type 2 diabetes mellitus is a disease in which traditional therapeutic strategies, such as optimization of the lifestyle, intake of metformin and sulfonylureas or glitazone prove secondarily inefficient in the short run. The discovery and use of new hypoglycemic agents, e.g. DPP-4 inhibitors, open up opportunities for the further improvement of glycemic control. This review contains data on mechanisms of action, efficacy and safety of DPP-4 inhibitors exemplified by sitagliptin and their possible effects on the cardiovascular system.

Arterial stiffness, renal function and renal blood flow in patients with coronary artery disease, arterial hypertension and type 2 diabetes mellitus

“…Вследствие макроангиопатии развиваются атеросклероз и его осложнения, с развитием микроангиопатии связаны ретинопатия и нефропатия. Более половины пациентов с СД2 умирают от сердечнососудистых осложнений (ССО) [8]. Диабетическая нефропатия стоит на втором месте после ССЗ среди причин смертности больных СД2 [9].…”